Incyte Maps Post-JAKAFI Growth With Pipeline Push and $4B Sales Target

Key Points

• Incyte is targeting $3 billion to $4 billion in non-JAKAFI sales by 2030, up from roughly $2 billion currently, supported by a broader late-stage pipeline and potential 15%–20% annual growth from 2030 to 2035.
• The company is preparing for JAKAFI’s loss of exclusivity after 2029, with JAKAFI XR formulary coverage expected to reach 70%–80% by year-end. Converting 10%–30% of patients to the extended-release version could preserve nearly $750 million in transition-period sales.
• Key pipeline programs are advancing across hematology, oncology and dermatology, including CALR antibody 989, KRAS G12D inhibitor 734, TGF-beta/PD-1 bispecific 890 and povorcitinib; Incyte is also expanding through the acquisition of Vega Therapeutics’ von Willebrand disease candidate latarcibart.

Incyte NASDAQ: INCY executives outlined a strategy centered on expanding its non-JAKAFI business, advancing a broader late-stage pipeline and preparing for the loss of exclusivity for JAKAFI after 2029.

Chief Executive Officer Bill Meury said the company’s pipeline has changed substantially over the past year, citing proof-of-concept data for its CALR antibody 989 in myelofibrosis and essential thrombocythemia, its KRAS G12D inhibitor in pancreatic cancer, and its TGF-beta-by-PD-1 program in colorectal cancer. He also pointed to phase III data for povorcitinib, which is under FDA review, and the acquisition of Vega Therapeutics and its von Willebrand disease candidate latarcibart.

Meury said Incyte’s core business excluding JAKAFI is annualizing at roughly $2 billion in sales. The company aims to increase that figure to $3 billion to $4 billion by 2030. If its pipeline programs are successfully developed and launched, he said Incyte has the potential to grow at a 15% to 20% compound annual rate from 2030 through 2035.

JAKAFI XR Conversion and MPN Pipeline

Meury said the company expects extended-release JAKAFI XR formulary coverage to approach 70% to 80% by year-end. According to Meury, major pharmacy benefit managers and health plans have placed XR on formulary at parity with immediate-release JAKAFI and at a price acceptable to both Incyte and payers.

Incyte has projected that 10% to 30% of JAKAFI patients could convert to XR before loss of exclusivity. At the midpoint of that range, Meury said the conversion could preserve nearly $750 million in sales during the transition. He characterized XR as a bridge rather than a primary driver of Incyte’s long-term value.

President and Global Head of R&D Pablo Cagnoni said 989 is already in pivotal development for second-line essential thrombocythemia, while a second-line myelofibrosis study is being implemented. The company plans to provide more details on the myelofibrosis trial design during its next earnings call.

For frontline myelofibrosis, Incyte expects to present data at the American Society of Hematology meeting from a cohort in which roughly two-thirds of patients received 989 monotherapy and one-third received 989 with ruxolitinib. Cagnoni said the data will help determine the design of a planned frontline trial expected to begin in early 2027.

The company is also discussing potential endpoints with the FDA. Cagnoni said Incyte believes measures including hemoglobin, platelets, blasts and spleen size could support a composite endpoint that better reflects disease modification. The company continues to have a “constructive dialogue” with the agency, he said, but retains a path to approve 989 using existing endpoints if necessary.

Incyte also plans to present preclinical data at ASH for a next-generation mutant CALR antibody that Cagnoni said has a longer half-life and greater potency against Type 1 and Type 2 CALR mutations. Separately, the company will present a preclinical package for a next-generation JAK2 V617F inhibitor designed to improve on its discontinued earlier program.

Solid-Tumor Programs Advance

At the European Society for Medical Oncology meeting, Incyte plans to provide an update on its KRAS G12D inhibitor, 734, in approximately 50 frontline pancreatic cancer patients treated in combination with either FOLFIRINOX or gemcitabine plus nab-paclitaxel. Cagnoni said the company expects to report strong efficacy data and six-month event-free survival, though progression-free survival is not yet mature.

He said Incyte views its efficacy and safety profile as comparable with that of its nearest competitor, while noting that patients in its study have had approximately 1.6 to 1.8 months longer treatment exposure. A phase III frontline pancreatic cancer study is enrolling and expanding globally, and Incyte plans to pursue an adjuvant pancreatic cancer program.

The company will also present data for 734 plus cetuximab in later-line colorectal cancer. Cagnoni said the response rate exceeded what would be expected from cetuximab alone and that the company intends to discuss a proposed pivotal trial with the FDA.

Incyte’s TGF-beta receptor II-by-PD-1 bispecific, 890, is being studied in microsatellite-stable colorectal cancer. Cagnoni said the drug’s design seeks to target TGF-beta receptor II only when the PD-1 arm is fully engaged, potentially avoiding the toxicity associated with systemic TGF-beta approaches. In a heavily pretreated group of about 100 patients, he said the program produced a 15% response rate with durable responses. The company plans to present data from about 50 frontline patients receiving 890 with FOLFOX and bevacizumab at ESMO, while its phase III trial is enrolling ahead of schedule.

Dermatology and Von Willebrand Disease

Meury said povorcitinib could address hidradenitis suppurativa in both pre-biologic and post-biologic populations. He said the company’s open-label extension data from more than 1,200 participants have been reassuring and that the benefit-risk profile differs from that of JAK inhibitors in other settings because of patient selection, dosing and monitoring.

Incyte is preparing a U.S. launch effort that will include a sales organization covering more than 10,000 HS specialists, peer-to-peer programs, consumer advertising and payer-access initiatives. Germany is the company’s initial international target market. Meury also said Incyte expects fourth-quarter data for povorcitinib in prurigo nodularis and for OPZELURA in HS.

On business development, Meury highlighted the Vega acquisition as an example of the company’s preferred approach: acquiring a de-risked, late-stage asset in an area aligned with Incyte’s hematology expertise. Latarcibart uses a different approach to treating von Willebrand disease by modulating anticoagulant protein S. Cagnoni said a database analysis cited by the company estimated that about 30,000 patients with von Willebrand disease could qualify for prophylaxis, while only about 2,000 currently receive it.

Meury said business development remains a priority as Incyte seeks to supplement its internal pipeline, but stressed the importance of deploying capital carefully.

About Incyte (NASDAQ:INCY)

Incyte Corporation is a biopharmaceutical company focused on discovering, developing and commercializing medicines for oncology and inflammatory diseases. Founded in 1991 and headquartered in Wilmington, Delaware, the company conducts research in areas including oncology, hematology, immunology and dermatology.

Incyte's commercial portfolio includes Jakafi (ruxolitinib), a treatment for certain myelofibrosis, polycythemia vera and graft-versus-host disease; Opzelura (ruxolitinib) cream for atopic dermatitis and nonsegmental vitiligo; and Pemazyre (pemigatinib) for selected cancers involving abnormal FGFR signaling.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.